Quick Answer
UroGen Pharma Ltd. reported Net Income Loss of -$153.49 million for the year ending 2025.
- UroGen Pharma Ltd. showed a decrease of -21.0% in Net Income Loss from 2024 to 2025.
- This data is from UroGen Pharma Ltd.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 11 years of available data (2015 to 2025), UroGen Pharma Ltd.'s Net Income Loss has declined by 1,109.7%.
- Historical annual values: Fiscal year 2025: -$153.49 million | Fiscal year 2024: -$126.87 million | Fiscal year 2023: -$102.24 million | Fiscal year 2022: -$109.78 million | Fiscal year 2021: -$110.82 million | Fiscal year 2020: -$128.48 million | Fiscal year 2019: -$105.15 million | Fiscal year 2018: -$75.66 million | Fiscal year 2017: -$20.00 million | Fiscal year 2016: -$1.94 million | Fiscal year 2015: -$12.69 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: